Janus Henderson Global Life Sciences FundJFNSX
Type
Mutual fund
Peer group
US equity: Healthcare
Net assets
$5.2B
Expense ratio
1.19%
1-year return
+36.6%
3 years, a year
+16.3%
5 years, a year
+9.1%
12-month yield
4.23%
Holdings
104
What it aims to do.
Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co. | 8.84% |
| JNJ Johnson & Johnson | 7.29% |
| AZN AstraZeneca PLC | 4.59% |
| ABBV AbbVie Inc. | 4.05% |
| UNH UnitedHealth Group Inc. | 3.13% |
| NVS Novartis AG | 2.86% |
| TMO Thermo Fisher Scientific Inc | 2.51% |
| PRAX Praxis Precision Medicines Inc | 2.45% |
| ARGX Argenx SE | 2.40% |
| ABT Abbott Laboratories | 2.40% |
More on JFNSX.
- JFNSX overview
- JFNSX holdings
- JFNSX risk
- JFNSX costs
- JFNSX money in and out
- JFNSX share classes
- Compare JFNSX with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.